<DOC>
	<DOCNO>NCT00692458</DOCNO>
	<brief_summary>The purpose study test MK0822 reduce risk bone metastasis woman breast cancer .</brief_summary>
	<brief_title>A Study Assess Effects MK0822 Reducing Risk Bone Metastasis Women With Breast Cancer ( 0822-029 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Confirmed primary State II Stage III breast cancer Patient receive adjuvant chemotherapy ( e.g. , cyclophosphamide , doxorubicin , carboplatin ) time randomization receive adjuvant chemotherapy least 6 week prior randomization visit ( Visit 2 ) . This inclusion criterion include hormone therapy , permit ( see inclusion criterion # 7 ) Patient receive hormonal therapy OR patient receive hormonal therapy ( e.g. , leuprolide , tamoxifen , anastrozole ) stable regimen least 3 month time screen ( Visit 1 ) . If patient HER2positive receiving trastuzumab treatment , must stable regimen least 1 month time Visit 1 Patient pregnant breastfeeding . All woman childbearing potential must negative urine pregnancy test screening ( Visit 1 ) Bone metastases history bone metastases Patient evidence distant metastasis ( e.g. , visceral , softtissue , brain ) Patient prior local regional recurrence breast cancer , contralateral tumor . DCIS ( ductal carcinoma insitu ) , LCIS ( local carcinoma insitu ) either ipsilateral contralateral breast permit Patient ANY following : 1. currently receive bisphosphonate drug therapy osteoporosis 2. treated oral bisphosphonate osteoporosis 3 month within 2 year prior Visit 1 , total 6 month time prior Visit 1 3. treat intravenous bisphosphonate within 12 month prior Visit 1 Patient history malignancy breast cancer &lt; 5 year prior sign inform consent , except adequately treat basal cell squamous cell skin cancer situ cervical cancer . Patients melanoma , leukemia , lymphoma , myeloproliferative disorder duration exclusionary Patient currently participate participate study investigational compound device within 30 day sign informed consent Patient currently participate time past participated breast cancer study register medication ( i.e. , approve regulatory agency resides ) test treatment breast cancer ( unapproved indication )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>